2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T54c,Circadian rhythms orchestrate immune activation and effector function, yet whether within-day timing influences chimeric antigen receptor (CAR) T-cell therapy outcomes remains unknown. We conducted an international, multicenter retrospective study of 1,052 adults with relapsed or refractory large B-cell lymphoma treated with CD19-directed CAR T-cell therapy across seven centers (2017-2025). The median infusion time was 11:48 AM (interquartile range, 11:06 AM-12:45 PM). Each hour later in infusion time was associated with an increased risk of progression, relapse, or death (hazard ratio 1.11; 95% CI, 1.03-1.20; P = 0.004) after adjustment for center, product, and key clinical variables. One-year progression-free survival (PFS) was 51.4% for early (<12:00 PM) versus 35.2% for late (≥12:00 PM) infusion, while overall survival was similar between groups. The PFS benefit was driven by lower relapse and higher complete response rates in the early infusion group. Although no differences were observed in immune toxicities, late infusion correlated with higher peak inflammatory markers and reduced day 7 CAR T-cell expansion. Together, these multicenter data provide the first clinical evidence that the timing of CAR T-cell infusion may influence therapeutic efficacy and support prospective evaluation of circadian-informed delivery strategies.31:T564,Circadian rhythms orchestrate immune activation and effector function, yet whether within-day timing influences chimeric antigen receptor (CAR) T-cell therapy outcomes remains unknown. We conducted an international, multicenter retrospective study of 1,052 adults with relapsed or refractory large B-cell lymphoma treated with CD19-directed CAR T-cell therapy across seven centers (2017-2025). The median infusion time was 11:48 AM (interquartile range, 11:06 AM-12:45 PM). Each hour later in infusion time was associated with an increased risk of progression, relapse, or death (hazard ratio 1.11; 95% CI, 1.03-1.20; P = 0.004) after adjustment for center, product, and key clinical variables. One-year progression-free survival (PFS) was 51.4% for early (<12:00 PM) versus 35.2% for late (≥12:00 PM) infusion, while overall survival was similar between groups. The PFS benefit was driven by lower relapse and higher complete response rates in the early infusion group. Although no differences were observed in immune toxicities, late infusion correlated with higher peak inflammatory markers and reduced day 7 CAR T-cell expansion. Together, these multicenter data provide the first clinical evidence that the timing of CAR T-cell infusion may influence therapeutic efficacy and support prospective evaluation of circadian-informed delivery strategies.32:T52f,Large B-cell lymphomas (LBCLs) are curable, but patients with residual disease after therapy invariably experience progression. Ultrasensitive methods to detect circulating tumor DNA (ctDNA) as minimal residual disease (MRD) may improve the determination of remission. We integrated data from five prospective studies of frontline anthracycline-based chemotherapy in patients with LBCL. Tumor-specific phased variants were identified from pretreatment samples and monitored at landmark time points. Serial plasma specimens were blindly analyzed for detectable ctDNA as MRD. MRD status was compared with conventional response criteria for prognosis of progression-free survival (PFS). We studied ctDNA-MRD in 137 patients by monitoring 409 plasma specimens over time. Detectable ctDNA rates decreased during therapy with 55% and 78% of patients achieving undetectable ctDNA after two cycles and at the end of therapy, respectively. After a median follow-up of 37 months, the 2-year PFS for patients with detectable versus undetectable ctDNA after two cycles was 67% versus 96% ( Ultrasensitive ctDNA detection after frontline LBCL therapy is more prognostic than conventional radiographic response criteria. A refined definition of remission with ctDNA-MRD may improve clinical and psychological outcomes for patients with LBCL.33:Ta3d, PURPOSE Large B-cell lymphomas (LBCLs) are curable, but patients with residual disease after therapy invariably experience progression. Ultrasensitive methods to detect circulating tumor DNA (ctDNA) as minimal residual disease (MRD) may improve the determination of remission. METHODS We integrated data from five prospective studies of frontline anthracycline-based chemotherapy in patients with LBCL. Tumor-specific phased variants were identified from pretreatment samples and monitored at landmark time points. Serial plasma specimens were blindly analyzed for detectable ctDNA as MRD. MRD status was compared with conventional response criteria for prognosis of progression-free survival (PFS). RESULTS We studied ctDNA-MRD in 137 patients by monitoring 409 plasma specimens over time. Detectable ctDNA rates decreased during therapy with 55% and 78% of patients achieving undetectable ctDNA after two cycles and at the end of therapy, respectively. After a median follow-up of 37 months, the 2-year PFS for patients with detectable versus undetectable ctDNA after two cycles was 67% versus 96% ( P = .0025; hazard ratio [HR], 6.9) and after therapy was 29% versus 97% ( P < .0001; HR, 28.7), respectively. Ninety-two (94%) patients with undetectable ctDNA at the end of therapy remained alive without progression, while 19 (68%) patients with detectable ctDNA progressed or died. MRD status at the end of therapy had greater prognostic utility than conventional lymphoma response criteria using positron emission tomography (PET) scans (HR, 3.6 for positive PET and 28.3 for detectable ctDNA). CONCLUSION Ultrasensitive ctDNA detection after frontline LBCL therapy is more prognostic than conventional radiographic response criteria. A refined definition of remission with ctDNA-MRD may improve clinical and psychological outcomes for patients with LBCL. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Large B-Cell Lymphoma: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Large B-Cell Lymphoma (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/Large%20B-Cell%20Lymphoma\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Large B-Cell Lymphoma\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/Large%20B-Cell%20Lymphoma\"}]}}"}}]],["$","$L2f",null,{"title":"Large B-Cell Lymphoma: Research & Clinical Takeaways","description":"Discover peer-reviewed research on Large B-Cell Lymphoma with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.1182/blood.2026033839","pmid":"42622258","title":"Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial","journal_title":"Blood Journal","journal_issn":"0006-4971","published_at":"2026-08-11T00:00:00.000Z","url":"https://doi.org/10.1182/blood.2026033839","source_score":19,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-26T06:20:06.379Z","updated_at":"2026-08-26T06:20:06.379Z","tags":[{"paper_doi":"10.1182/blood.2026033839","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"brand","value":"Epkinly","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"condition","value":"Large B-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"generic","value":"cyclophosphamide","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"generic","value":"doxorubicin","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"generic","value":"epcoritamab","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"generic","value":"prednisone","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"generic","value":"rituximab","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"generic","value":"vincristine","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"modality","value":"Bispecific Antibody","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"modality","value":"Chemoimmunotherapy","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"sample_size","value":"n=47","value_numeric":47},{"paper_doi":"10.1182/blood.2026033839","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"study_design","value":"Phase 1b/2 Single-Arm Trial","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"warning","value":"No direct comparator arm was included; the 2-year PFS/OS figures cannot be formally compared to historical R-CHOP data without adjustment for patient selection.","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"warning","value":"The brand name 'Epkinly' is used for epcoritamab; confirm regulatory approval status in your region for the frontline LBCL indication, as this trial is investigational.","value_numeric":null},{"paper_doi":"10.1182/blood.2026033839","tag_type":"warning","value":"The phase 3 confirmatory trial (NCT04663347 or successor) is described as 'ongoing' — clinicians should check for updated results before adopting this regimen.","value_numeric":null}],"summaries":{"what_studied":"Phase 1b/2 single-arm study (EPCORE NHL-2, Arm 1) evaluating epcoritamab added to R-CHOP (6 cycles) for 1 year total in 47 adults with newly diagnosed CD20+ LBCL and high-risk IPI scores of 3–5.","key_result":"ORR was 98% and CR rate was 85%; at median follow-up of 44.2 months, median DOCR, PFS, and OS were not reached; estimated 2-year PFS was 80% and 2-year OS was 87%. MRD negativity was achieved in 100% of evaluable patients. CRS occurred in 60% of patients but was predominantly grade 1–2 and all events resolved.","limitations":"Single-arm design with no comparator limits conclusions about benefit over R-CHOP alone; small sample size (n=47) reduces precision; investigator-assessed endpoints introduce potential bias.","practice_takeaway":"For high-risk newly diagnosed LBCL (IPI 3–5), epcoritamab plus R-CHOP showed durable responses in this early-phase study — but wait for the ongoing phase 3 trial before changing frontline practice. CRS was common yet manageable, so step-up dosing protocols and monitoring should be in place."}},{"doi":"10.1126/sciimmunol.aef4134","pmid":"42497245","title":"Genomic correlates of clinical CAR T cell activity","journal_title":"Science Immunology","journal_issn":"2470-9468","published_at":"2026-07-24T00:00:00.000Z","url":"https://doi.org/10.1101/2025.10.08.25337584","source_score":94,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-31T13:37:09.514Z","updated_at":"2026-07-31T13:37:09.514Z","tags":[{"paper_doi":"10.1126/sciimmunol.aef4134","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1126/sciimmunol.aef4134","tag_type":"brand","value":"Yescarta","value_numeric":null},{"paper_doi":"10.1126/sciimmunol.aef4134","tag_type":"category","value":"Immunology","value_numeric":null},{"paper_doi":"10.1126/sciimmunol.aef4134","tag_type":"condition","value":"Cytokine Release Syndrome","value_numeric":null},{"paper_doi":"10.1126/sciimmunol.aef4134","tag_type":"condition","value":"Diffuse Large B-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1126/sciimmunol.aef4134","tag_type":"condition","value":"Immune Effector Cell-Associated Neurotoxicity Syndrome","value_numeric":null},{"paper_doi":"10.1126/sciimmunol.aef4134","tag_type":"condition","value":"Large B-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1126/sciimmunol.aef4134","tag_type":"generic","value":"axicabtagene ciloleucel","value_numeric":null},{"paper_doi":"10.1126/sciimmunol.aef4134","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1126/sciimmunol.aef4134","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1126/sciimmunol.aef4134","tag_type":"modality","value":"CAR T Cell Therapy","value_numeric":null},{"paper_doi":"10.1126/sciimmunol.aef4134","tag_type":"sample_size","value":"n=236","value_numeric":236},{"paper_doi":"10.1126/sciimmunol.aef4134","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1126/sciimmunol.aef4134","tag_type":"study_design","value":"Retrospective Genomic Case-Control Study with Functional Validation","value_numeric":null},{"paper_doi":"10.1126/sciimmunol.aef4134","tag_type":"warning","value":"Analysis was limited to European-ancestry patients; findings may not generalize to other ancestral groups.","value_numeric":null},{"paper_doi":"10.1126/sciimmunol.aef4134","tag_type":"warning","value":"Sample sizes in subgroup analyses (e.g., n=6 STXBP2 variant carriers) are small, and most findings do not survive Bonferroni correction; results should be considered hypothesis-generating.","value_numeric":null},{"paper_doi":"10.1126/sciimmunol.aef4134","tag_type":"warning","value":"The paper was originally posted as a preprint (October 2025) and published in Science Immunology (July 2026); the full peer-reviewed version should be consulted for any amendments.","value_numeric":null},{"paper_doi":"10.1126/sciimmunol.aef4134","tag_type":"warning","value":"The study was funded by Kite Pharma, manufacturer of axicabtagene ciloleucel; several authors are Kite employees. Readers should weigh potential industry bias.","value_numeric":null},{"paper_doi":"10.1126/sciimmunol.aef4134","tag_type":"warning","value":"The STXBP2 toxicity finding was significant in ZUMA-1 but not replicated in ZUMA-7; cross-trial differences in patient population, prior therapy burden, and management may explain this discrepancy.","value_numeric":null}],"summaries":{"what_studied":"Whole germline sequencing was integrated with biomarker and functional analyses from 86 (ZUMA-1) and 150 (ZUMA-7) lymphoma patients treated with axicabtagene ciloleucel CAR T cell therapy to identify germline variants influencing CAR T cell toxicity (CRS/ICANS) and pharmacokinetics (expansion).","key_result":"Putative deleterious STXBP2 variants were found in 15.4% (6/39) of the ZUMA-1 toxicity cohort vs. 0% of controls (OR >1.44, p=0.025); all 6 reached the toxicity endpoint by day 10, with an STXBP2 variant hazard ratio of 3.72 (95% CI 1.53–9.01) for toxicity. ADAMTSL3 variants were nominally protective across both trials. PTPN22 variants strongly associated with peak CAR T cell expansion in both cohorts (ZUMA-1: p=6.18×10⁻⁹; ZUMA-7: p=7.16×10⁻¹⁵), with variant carriers (~5% of subjects) achieving the highest expansion levels.","limitations":"- Analysis restricted to European-ancestry patients, limiting generalizability to other populations.\n- STXBP2 enrichment in the toxicity cohort was confirmed in ZUMA-1 but **not** replicated in ZUMA-7, likely due to differences in disease burden, prior therapy lines, and baseline inflammation.\n- In vitro CRISPR knockouts and variant overexpression may not fully recapitulate heterozygous germline variant biology seen in patients.","practice_takeaway":"Germline variants in STXBP2 (toxicity risk), ADAMTSL3 (protection), and PTPN22 (enhanced expansion/efficacy) shape CAR T cell behavior in lymphoma — pre-treatment germline screening may eventually help stratify toxicity risk and predict response, and is especially relevant as allogeneic CAR T products scale up with shared donors."}},{"doi":"10.3324/haematol.2026.300993","pmid":"42389816","title":"Female sex is associated with superior outcomes in patients treated with CD19-directed CAR T-cell therapy for large B-cell lymphoma","journal_title":"Haematologica","journal_issn":"1592-8721","published_at":"2026-07-02T00:00:00.000Z","url":"https://doi.org/10.3324/haematol.2026.300993","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-06T13:36:22.123Z","updated_at":"2026-07-06T13:36:22.123Z","tags":[{"paper_doi":"10.3324/haematol.2026.300993","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.3324/haematol.2026.300993","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.3324/haematol.2026.300993","tag_type":"condition","value":"Large B-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.3324/haematol.2026.300993","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.3324/haematol.2026.300993","tag_type":"modality","value":"CAR T-Cell Therapy","value_numeric":null},{"paper_doi":"10.3324/haematol.2026.300993","tag_type":"modality","value":"CD19-Directed Immunotherapy","value_numeric":null},{"paper_doi":"10.3324/haematol.2026.300993","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.3324/haematol.2026.300993","tag_type":"warning","value":"Sample size is unknown; the sample_size tag has been omitted.","value_numeric":null},{"paper_doi":"10.3324/haematol.2026.300993","tag_type":"warning","value":"Study design and level of evidence could not be determined from available text.","value_numeric":null},{"paper_doi":"10.3324/haematol.2026.300993","tag_type":"warning","value":"The full text body of the paper was not extractable — all pages beyond the title/metadata were blank in the source. Summaries, tags, and key results are based solely on the title, author list, and journal metadata. Specific outcomes, sample sizes, study design, and statistical results could not be verified. The 'practice_changing' impact flag is tentative given the suggestive title but cannot be confirmed without full data.","value_numeric":null}],"summaries":{"what_studied":"This study evaluated whether female sex is associated with improved outcomes in patients with large B-cell lymphoma (LBCL) treated with CD19-directed CAR T-cell therapy.","key_result":"Female sex was associated with superior outcomes compared to male sex in patients receiving CD19-directed CAR T-cell therapy for LBCL; specific outcome metrics (e.g., PFS, OS rates) were not available in the extracted text.","limitations":"Full text body was not extractable beyond the title page and metadata, preventing assessment of sample size, follow-up duration, study design details, or confounding variable adjustment.","practice_takeaway":"Clinicians should be aware that female sex may be a prognostic factor in LBCL patients receiving CD19-directed CAR T-cell therapy; however, confirmation of specific numbers and clinical implications requires review of the full published article."}},{"doi":"10.1182/bloodadvances.2026020988","pmid":"42341324","title":"Meta-analysis of survival by phased-variant ctDNA and PET response in large B-cell lymphoma","journal_title":"Blood Advances","journal_issn":"2473-9529","published_at":"2026-06-24T00:00:00.000Z","url":"https://doi.org/10.1182/bloodadvances.2026020988","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-19T06:28:57.970Z","updated_at":"2026-08-19T06:28:57.970Z","tags":[{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"condition","value":"Diffuse Large B-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"condition","value":"High Grade B-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"condition","value":"Large B-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"condition","value":"Primary Mediastinal B-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"generic","value":"cyclophosphamide","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"generic","value":"rituximab","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"modality","value":"Chemoimmunotherapy","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"modality","value":"Circulating Tumor DNA (ctDNA) Testing","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"modality","value":"PET Imaging","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"sample_size","value":"n=367","value_numeric":367},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"study_design","value":"Meta-Analysis","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"warning","value":"Cell-of-origin (GCB vs. non-GCB) data were only available for the Roschewski cohort, limiting subgroup generalizability.","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"warning","value":"R-CHOP regimen data were only partially reported across cohorts (missing for Roschewski cohort), so treatment homogeneity across the meta-analysis cannot be fully confirmed.","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"warning","value":"The full text available contains only supplementary tables and a CONSORT diagram; primary survival outcome data (HRs, OS/PFS curves, p-values) are not present in the provided source and could not be summarized.","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2026020988","tag_type":"warning","value":"The meta-analysis sample size of 367 reflects eligible patients across three cohorts; total enrolled was 422, but 55 were excluded from the meta-analysis for unstated reasons per the CONSORT diagram reference.","value_numeric":null}],"summaries":{"what_studied":"This meta-analysis pooled three cohorts (Roschewski, Wang, Krupka cohort 2; total N=367 in meta-analysis) to evaluate the prognostic value of combined phased-variant ctDNA (MRD) testing and end-of-treatment PET response in large B-cell lymphoma patients.","key_result":"Across cohorts, MRD−/PET− was the most common end-of-treatment category (66–72% of patients); MRD+/PET+ occurred in 10–12%, and discordant groups (MRD−/PET+ or MRD+/PET−) each comprised ~7–13% of patients. Specific survival outcome data (HRs, OS/PFS rates) are not fully reported in the available text.","limitations":"Only two ctDNA testing platforms were used (Foresight Diagnostics and University of Cambridge), limiting generalizability; staging and cell-of-origin data were incomplete across cohorts; median follow-up was relatively short in one cohort (24.5 months).","practice_takeaway":"Combined ctDNA MRD and PET assessment at end of treatment identifies a meaningful subset (~10–13%) of large B-cell lymphoma patients who are MRD+/PET+ and may warrant intensified follow-up or treatment strategies. Discordant MRD/PET results (each ~7–13%) highlight that neither test alone captures full residual disease burden."}},{"doi":"10.1200/jco-26-00947","pmid":"42274647","title":"High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis","journal_title":"Journal of Clinical Oncology","journal_issn":"0732-183X","published_at":"2026-06-11T00:00:00.000Z","url":"https://doi.org/10.1200/jco-26-00947","source_score":55,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-24T06:18:26.196Z","updated_at":"2026-08-24T06:18:26.196Z","tags":[{"paper_doi":"10.1200/jco-26-00947","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1200/jco-26-00947","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1200/jco-26-00947","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1200/jco-26-00947","tag_type":"condition","value":"Large B-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1200/jco-26-00947","tag_type":"condition","value":"Secondary CNS Lymphoma","value_numeric":null},{"paper_doi":"10.1200/jco-26-00947","tag_type":"generic","value":"methotrexate","value_numeric":null},{"paper_doi":"10.1200/jco-26-00947","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1200/jco-26-00947","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1200/jco-26-00947","tag_type":"modality","value":"Antimetabolite","value_numeric":null},{"paper_doi":"10.1200/jco-26-00947","tag_type":"modality","value":"CNS Prophylaxis","value_numeric":null},{"paper_doi":"10.1200/jco-26-00947","tag_type":"sample_size","value":"n=1923","value_numeric":1923},{"paper_doi":"10.1200/jco-26-00947","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1200/jco-26-00947","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1200/jco-26-00947","tag_type":"warning","value":"Brand name tags are not applicable here as methotrexate is a generic drug used off-label in this context.","value_numeric":null},{"paper_doi":"10.1200/jco-26-00947","tag_type":"warning","value":"DHL/THL was not included as a formal UHR subgroup due to inconsistent reporting; CNS relapse pattern in this group may differ and warrants separate consideration.","value_numeric":null},{"paper_doi":"10.1200/jco-26-00947","tag_type":"warning","value":"The impact_flag 'practice_changing' is applied based on the JCO editor's explicit commentary that these data 'should definitively end the practice of CNS prophylaxis with methotrexate in LBCL,' but the study is retrospective and not a randomized trial.","value_numeric":null},{"paper_doi":"10.1200/jco-26-00947","tag_type":"warning","value":"The no HD-MTX group had a notably earlier median diagnosis date (Nov 2012 vs. Dec 2016) and longer follow-up (76 vs. 41 months), which may introduce era-related confounding despite sensitivity analyses.","value_numeric":null}],"summaries":{"what_studied":"This international multicenter retrospective analysis examined whether high-dose methotrexate (HD-MTX) CNS prophylaxis reduces CNS relapse in 1,923 ultra high-risk (UHR) large B-cell lymphoma (LBCL) patients (CNS-IPI 5–6, testicular/renal/adrenal/breast involvement, or ≥3 extranodal sites), treated with (n=872) or without (n=1,051) HD-MTX after R-CHOP/R-CHOP-like therapy, with a landmark analysis at 6 months (n=1,555).","key_result":"No significant difference in 3-year CNS relapse was seen between no HD-MTX vs. HD-MTX groups overall (9.3% vs. 8.1%; adjusted HR 1.13, 95% CI 0.82–1.57), for isolated CNS relapse (5.9% vs. 5.7%; adjusted HR 1.03, 95% CI 0.69–1.53), or in the landmark cohort (6.7% vs. 6.6%; adjusted HR 0.95, 95% CI 0.62–1.44); no individual UHR subgroup showed benefit. Median post-CNS relapse OS was only 3.8 months regardless of HD-MTX receipt.","limitations":"- Retrospective design with inherent selection bias: HD-MTX patients were younger, fitter, and had more extranodal site involvement, despite multivariable and propensity-score adjustments.\n- Variable HD-MTX dosing, timing, infusion schedules, and cycle numbers across 47+ centers, with no standardized protocol.\n- Baseline CNS screening was performed in only ~37–50% of patients and was not mandated, risking inclusion of occult CNS disease.","practice_takeaway":"These data strongly support abandoning routine HD-MTX CNS prophylaxis even in the highest-risk LBCL patients, as no meaningful reduction in CNS relapse was found in any UHR subgroup. Clinicians should prioritize sensitive baseline CNS screening and watch for emerging data on bispecific antibodies and CAR-T cells as potential alternatives."}},{"doi":"10.1182/blood.2025032270","pmid":"42237652","title":"Five-year survival outcomes from TRANSCEND NHL 001 of lisocabtagene maraleucel in R/R LBCL","journal_title":"Blood Journal","journal_issn":"0006-4971","published_at":"2026-06-03T00:00:00.000Z","url":"https://doi.org/10.1182/blood.2025032270","source_score":9,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-10T14:24:30.897Z","updated_at":"2026-06-10T14:24:30.897Z","tags":[{"paper_doi":"10.1182/blood.2025032270","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1182/blood.2025032270","tag_type":"brand","value":"Breyanzi","value_numeric":null},{"paper_doi":"10.1182/blood.2025032270","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1182/blood.2025032270","tag_type":"condition","value":"Large B-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1182/blood.2025032270","tag_type":"condition","value":"Relapsed/Refractory B-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1182/blood.2025032270","tag_type":"generic","value":"lisocabtagene maraleucel","value_numeric":null},{"paper_doi":"10.1182/blood.2025032270","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1182/blood.2025032270","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1182/blood.2025032270","tag_type":"modality","value":"CAR-T Cell Therapy","value_numeric":null},{"paper_doi":"10.1182/blood.2025032270","tag_type":"sample_size","value":"n=270","value_numeric":270},{"paper_doi":"10.1182/blood.2025032270","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1182/blood.2025032270","tag_type":"study_design","value":"Single-Arm Phase 1 Trial with Long-Term Follow-Up","value_numeric":null},{"paper_doi":"10.1182/blood.2025032270","tag_type":"warning","value":"Phase 1 trial design (NCT02631044) limits generalizability compared to a randomized trial.","value_numeric":null},{"paper_doi":"10.1182/blood.2025032270","tag_type":"warning","value":"The leukapheresed set (n=345) is the most conservative and clinically relevant intention-to-treat-like population, with a notably lower 5-year OS of 33% vs. 38% in efficacy-evaluable patients.","value_numeric":null},{"paper_doi":"10.1182/blood.2025032270","tag_type":"warning","value":"The LTFU subgroup (n=84) consists only of patients alive at end-of-study who enrolled in long-term follow-up — this is a survivor-selected population and the 78% 5-year OS should not be generalized to all liso-cel recipients. The efficacy-evaluable set (n=257) is the more representative denominator.","value_numeric":null}],"summaries":{"what_studied":"Five-year survival outcomes of lisocabtagene maraleucel (liso-cel) CAR-T therapy in 270 treated patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) from the TRANSCEND NHL 001 trial and a separate long-term follow-up (LTFU) study.","key_result":"Among 257 efficacy-evaluable patients, median OS was 27.5 months with a 5-year OS rate of 38%; 5-year DSS rate was 52%. In the LTFU subgroup still alive at end-of-study (n=84), 5-year OS was 78% and 5-year DSS was 92%. Most deaths occurred within 2 years of infusion; no new late safety signals were observed.","limitations":"LTFU subgroup (n=84) is highly selected — only patients alive at end-of-study who enrolled in follow-up, which inflates their OS/DSS estimates. Single-arm trial design limits causal inference. No comparator arm for long-term outcomes.","practice_takeaway":"For patients with R/R LBCL who respond to liso-cel and survive past 2 years, long-term cure appears achievable (~78% 5-year OS in survivors). Clinicians can counsel patients that late severe toxicities are rare, but early mortality risk is highest in the first 2 years post-infusion."}},{"doi":"10.1200/jco-25-03051","pmid":"42044466","title":"Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy","journal_title":"Journal of Clinical Oncology","journal_issn":"0732-183X","published_at":"2026-04-27T00:00:00.000Z","url":"https://doi.org/10.1200/jco-25-03051","source_score":60,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-05T13:38:52.701Z","updated_at":"2026-07-05T13:38:52.701Z","tags":[{"paper_doi":"10.1200/jco-25-03051","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1200/jco-25-03051","tag_type":"brand","value":"Breyanzi","value_numeric":null},{"paper_doi":"10.1200/jco-25-03051","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1200/jco-25-03051","tag_type":"condition","value":"Diffuse Large B-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1200/jco-25-03051","tag_type":"condition","value":"Large B-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1200/jco-25-03051","tag_type":"generic","value":"lisocabtagene maraleucel","value_numeric":null},{"paper_doi":"10.1200/jco-25-03051","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1200/jco-25-03051","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1200/jco-25-03051","tag_type":"modality","value":"Autologous Stem Cell Transplantation","value_numeric":null},{"paper_doi":"10.1200/jco-25-03051","tag_type":"modality","value":"CAR T-Cell Therapy","value_numeric":null},{"paper_doi":"10.1200/jco-25-03051","tag_type":"modality","value":"Circulating Tumor DNA / Liquid Biopsy","value_numeric":null},{"paper_doi":"10.1200/jco-25-03051","tag_type":"sample_size","value":"n=136","value_numeric":136},{"paper_doi":"10.1200/jco-25-03051","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1200/jco-25-03051","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1200/jco-25-03051","tag_type":"warning","value":"PhasED-Seq MRD assessment is investigational and not FDA-approved for this indication—clinical deployment outside trials requires further regulatory review.","value_numeric":null},{"paper_doi":"10.1200/jco-25-03051","tag_type":"warning","value":"Several authors are employees or equity holders of Bristol Myers Squibb (manufacturer of liso-cel) or Foresight Diagnostics/Natera (developers of PhasED-Seq), representing substantial conflicts of interest.","value_numeric":null},{"paper_doi":"10.1200/jco-25-03051","tag_type":"warning","value":"Significant sex imbalance in the MRD-evaluable cohort (liso-cel: 46% male vs. SOC: 68% male), which was also present in the ITT population; potential impact on generalizability is not discussed.","value_numeric":null},{"paper_doi":"10.1200/jco-25-03051","tag_type":"warning","value":"This is a correlative/exploratory substudy of TRANSFORM (n=136 MRD-evaluable of 184 randomized); results are hypothesis-generating and should be interpreted cautiously.","value_numeric":null}],"summaries":{"practice_takeaway":"ctDNA-MRD negativity after liso-cel is deeper and more durable than after ASCT, and adds prognostic value beyond PET—especially after CAR T, where PET can be confounded by inflammatory changes. Consider ctDNA-MRD as a complementary tool alongside PET when monitoring treatment response and predicting relapse in second-line LBCL.","what_studied":"This correlative analysis from the phase III TRANSFORM RCT evaluated ctDNA-MRD (using ultrasensitive PhasED-Seq) in 136 patients with second-line ASCT-eligible relapsed/refractory large B-cell lymphoma (LBCL), comparing liso-cel versus salvage immunochemotherapy + HDCT/ASCT at predefined time points (baseline, day 43, 64, and 126).","key_result":"More patients achieved MRD negativity with liso-cel vs. SOC (62% vs. 38%; P=.01). Among day-126 MRDneg patients, liso-cel showed superior EFS (HR 3.9, 95% CI 1.4–10.6; P=.004), PFS (HR 4.6, 95% CI 1.6–13.2; P=.002), and DOR (HR 3.4, 95% CI 1.2–9.3; P=.01) vs. ASCT. In patients with both CR and MRDneg, 4/25 liso-cel vs. 11/17 SOC patients had an EFS event (HR 6.7, 95% CI 2.1–21.2; P<.001). MRDpos reversion by month 12 occurred in 9/15 ASCT patients vs. 0/20 liso-cel patients. ctDNA-MRD remained independently prognostic for EFS after adjusting for PET response, while PET predicted outcomes only in the liso-cel arm.","limitations":"- 14.5% of patients were non-evaluable for ctDNA (mostly low tumor burden), potentially introducing selection bias.\n- PhasED-Seq for MRD assessment is investigational and not FDA-cleared for this indication.\n- Exploratory/correlative design; findings require prospective validation."}},{"doi":"10.1182/bloodadvances.2025019322","pmid":"41785308","title":"Glofitamab crosses the blood-brain barrier and exhibits activity against primary and secondary CNS lymphoma","journal_title":"Blood Advances","journal_issn":"2473-9529","published_at":"2026-03-06T00:00:00.000Z","url":"https://doi.org/10.1182/bloodadvances.2025019322","source_score":40,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-05-06","doi":"10.1182/bloodadvances.2025019322","days":"14","issn":"2473-9529","rank":"4","field":"Clinical Medicine","score":"40","category":"Hematology","categories":["Hematology"],"_categories":["Hematology"]},"pubmed":{"doi":"10.1182/bloodadvances.2025019322","title":"Glofitamab crosses the blood-brain barrier and exhibits activity against primary and secondary CNS lymphoma.","journal":"Blood advances","methods":"","results":"","abstract":"","keywords":[],"pubmed_id":"41785308","conclusions":"","publication_date":"2026-03-06T00:00:00"},"crossref":{"DOI":"10.1182/bloodadvances.2025019322","URL":"https://doi.org/10.1182/bloodadvances.2025019322","ISSN":["2473-9529","2473-9537"],"link":[{"URL":"https://ashpublications.org/bloodadvances/article-pdf/10/9/3128/2516181/blooda_adv-2025-019322-main.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https://ashpublications.org/bloodadvances/article-pdf/10/9/3128/2516181/blooda_adv-2025-019322-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"3128-3132","type":"journal-article","issue":"9","score":1,"title":["Glofitamab crosses the blood-brain barrier and exhibits activity against primary and secondary CNS lymphoma"],"author":[{"given":"Marie Anne-Catherine","family":"Neumann","sequence":"first","affiliation":[{"name":"1Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany"},{"name":"2Cancer Center Cologne Essen, Partner Site Cologne, Cologne, Germany"},{"name":"3Cologne Lymphoma Working Group, Cologne, Germany"}]},{"given":"Jessica","family":"Schneider","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany"}]},{"given":"Max","family":"Szameitat","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany"}]},{"given":"Philipp","family":"Schommers","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany"}]},{"given":"Sven","family":"Borchmann","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany"},{"name":"2Cancer Center Cologne Essen, Partner Site Cologne, Cologne, Germany"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany"},{"name":"2Cancer Center Cologne Essen, Partner Site Cologne, Cologne, Germany"}]},{"given":"Peter","family":"Borchmann","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany"},{"name":"2Cancer Center Cologne Essen, Partner Site Cologne, Cologne, Germany"},{"name":"3Cologne Lymphoma Working Group, Cologne, Germany"}]},{"given":"Jan-Michel","family":"Heger","sequence":"additional","affiliation":[{"name":"1Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany"},{"name":"2Cancer Center Cologne Essen, Partner Site Cologne, Cologne, Germany"},{"name":"3Cologne Lymphoma Working Group, Cologne, Germany"},{"name":"4Mildred Scheel School of Oncology Aachen Bonn Cologne Düsseldorf, Faculty of Medicine and University Hospital Cologne, Cologne, Germany"}]}],"issued":{"date-parts":[[2026,5,1]]},"member":"234","prefix":"10.1182","source":"Crossref","volume":"10","created":{"date-time":"2026-03-05T18:59:03Z","timestamp":1772737143000,"date-parts":[[2026,3,5]]},"indexed":{"date-time":"2026-05-08T20:12:39Z","timestamp":1778271159782,"date-parts":[[2026,5,8]]},"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://ashpublications.org/bloodadvances/article/10/9/3128/566938/Glofitamab-crosses-the-blood-brain-barrier-and"}},"subtitle":[],"deposited":{"date-time":"2026-05-08T19:18:10Z","timestamp":1778267890000,"date-parts":[[2026,5,8]]},"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"published":{"date-parts":[[2026,5,1]]},"publisher":"American Society of Hematology","reference":[{"DOI":"10.1056/NEJMoa2116133","key":"2026050815180344400_bib1","year":"2022","issue":"7","author":"Locke","volume":"386","first-page":"640","unstructured":null,"article-title":"Axicabtagene ciloleucel as second-line therapy for large b-cell lymphoma","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(22)00662-6","key":"2026050815180344400_bib2","year":"2022","issue":"10343","author":"Kamdar","volume":"399","first-page":"2294","unstructured":null,"article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa2206913","key":"2026050815180344400_bib3","year":"2022","issue":"24","author":"Dickinson","volume":"387","first-page":"2220","unstructured":null,"article-title":"Glofitamab for relapsed or refractory diffuse large b-cell lymphoma","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1038/s43018-025-00921-6","key":"2026050815180344400_bib4","year":"2025","issue":"3","author":"Kim","volume":"6","first-page":"528","unstructured":null,"article-title":"Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial","journal-title":"Nat Cancer","doi-asserted-by":"crossref"},{"DOI":"10.1186/s13045-023-01508-3","key":"2026050815180344400_bib5","year":"2023","issue":"1","author":"Epperla","volume":"16","first-page":"111","unstructured":null,"article-title":"Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study","journal-title":"J Hematol Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1182/bloodadvances.2023010336","key":"2026050815180344400_bib6","year":"2023","issue":"18","author":"Ayuk","volume":"7","first-page":"5316","unstructured":null,"article-title":"Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study","journal-title":"Blood Adv","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.2024024168","key":"2026050815180344400_bib7","year":"2024","issue":"4","author":"Godfrey","volume":"144","first-page":"457","unstructured":null,"article-title":"Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1093/neuonc/noab020","key":"2026050815180344400_bib8","year":"2021","issue":"7","author":"Barajas","volume":"23","first-page":"1056","unstructured":null,"article-title":"Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)","journal-title":"Neuro Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.2024027877","key":"2026050815180344400_bib9","year":"2025","issue":"11","author":"Pelzl","volume":"146","first-page":"1300","unstructured":null,"article-title":"Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ccell.2025.05.013","key":"2026050815180344400_bib10","year":"2025","issue":"8","author":"Stahl","volume":"43","first-page":"1476","unstructured":null,"article-title":"CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma","journal-title":"Cancer Cell","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(24)01774-4","key":"2026050815180344400_bib11","year":"2024","issue":"10466","author":"Abramson","volume":"404","first-page":"1940","unstructured":null,"article-title":"Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.2023022020","key":"2026050815180344400_bib12","year":"2024","issue":"6","author":"Heger","volume":"143","first-page":"522","unstructured":null,"article-title":"Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA","journal-title":"Blood","doi-asserted-by":"crossref"}],"short-title":[],"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,5,12]]}},"update-policy":"https://doi.org/10.1182/blood.2019cm0000","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"original-title":[],"container-title":["Blood Advances"],"published-other":{"date-parts":[[2026,5,12]]},"published-print":{"date-parts":[[2026,5,12]]},"reference-count":12,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,5,1]]},"references-count":12,"short-container-title":[],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1182/bloodadvances.2025019322","is_oa":true,"title":"Glofitamab crosses the blood-brain barrier and exhibits activity against primary and secondary CNS lymphoma","updated":"2026-05-08T16:02:47+00:00","published_date":"2026-03-05","best_oa_location":{"url":"https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2025019322/2507132/bloodadvances.2025019322.pdf","pmh_id":null,"url_for_pdf":"https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2025019322/2507132/bloodadvances.2025019322.pdf","url_for_landing_page":"https://doi.org/10.1182/bloodadvances.2025019322"}}},"created_at":"2026-05-07T22:51:15.872Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1182/bloodadvances.2025019322","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025019322","tag_type":"brand","value":"Columvi","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025019322","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025019322","tag_type":"condition","value":"Large B-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025019322","tag_type":"condition","value":"Primary CNS Lymphoma","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025019322","tag_type":"condition","value":"Secondary CNS Lymphoma","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025019322","tag_type":"generic","value":"glofitamab","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025019322","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025019322","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025019322","tag_type":"modality","value":"Bispecific Antibody","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025019322","tag_type":"sample_size","value":"n=8","value_numeric":8},{"paper_doi":"10.1182/bloodadvances.2025019322","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025019322","tag_type":"study_design","value":"Case Series","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025019322","tag_type":"warning","value":"Brand name 'Columvi' assumed for glofitamab; confirm local approval status. The paper does not specify patient age or sex distributions explicitly. Most SCNSL patients received concurrent agents, making it difficult to attribute responses to glofitamab alone. The in vitro killing assay used obinutuzumab-pretreated samples during cycle 1, which may have influenced glofitamab equivalent concentration interpolation.","value_numeric":null}],"summaries":{"what_studied":"This case series evaluated glofitamab (a CD20×CD3 bispecific antibody) in 8 consecutive patients with relapsed/refractory primary CNS lymphoma (PCNSL, n=2) or secondary CNS lymphoma (SCNSL, n=6), including pharmacokinetic measurement of glofitamab in paired plasma and CSF samples.","key_result":"7 of 8 patients (87.5%) responded: 4 complete responses (CR) and 3 partial responses (PR). Both PCNSL patients received glofitamab as a single agent, achieved CR after 12 cycles, and remain in remission. CSF glofitamab concentrations were detectable in 4 of 5 samples and were <0.1% of plasma levels, yet were sufficient to kill B-cell lymphoma cells in vitro. Grade 1–2 cytokine release syndrome occurred in 3 patients; no neurotoxicity was observed.","limitations":"Very small sample size (n=8); most SCNSL patients received concurrent agents (e.g., methotrexate, BTK inhibitors) or glofitamab as bridging to CAR T-cell therapy, limiting assessment of single-agent activity; potential selection bias from case-by-case treatment decisions.","practice_takeaway":"Glofitamab crosses the blood-brain barrier at detectable, cytotoxic concentrations and showed high response rates in both PCNSL and SCNSL with a manageable safety profile. Consider it as a bridging or standalone option in relapsed/refractory CNS lymphoma, pending larger prospective data."}},{"doi":"10.1182/blood.2025032307","pmid":"41701973","title":"Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma","journal_title":"Blood","journal_issn":"0006-4971","published_at":"2026-02-17T00:00:00.000Z","url":"https://doi.org/10.1182/blood.2025032307","source_score":22,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2026-05-12","doi":"10.1182/blood.2025032307","days":"7","issn":"0006-4971","rank":"2","field":"Clinical Medicine","score":"22","category":"Hematology","categories":["Hematology"],"_categories":["Hematology"]},"pubmed":{"doi":"10.1182/blood.2025032307","title":"Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma.","journal":"Blood","methods":"","results":"","abstract":"In this retrospective analysis of 584 patients who received chimeric antigen receptor T-cell therapy for large B-cell lymphoma at 6 Australian centers, no association was found between time of infusion and outcome, accounting for confounders, suggesting minimal clinical impact of chronobiology in this setting.","keywords":[],"pubmed_id":"41701973","conclusions":"","publication_date":"2026-02-17T00:00:00"},"crossref":{"DOI":"10.1182/blood.2025032307","URL":"https://doi.org/10.1182/blood.2025032307","ISSN":["0006-4971","1528-0020"],"link":[{"URL":"https://ashpublications.org/blood/article-pdf/147/19/2272/2517416/blood_bld-2025-032307-main.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https://ashpublications.org/blood/article-pdf/147/19/2272/2517416/blood_bld-2025-032307-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"2272-2277","type":"journal-article","issue":"19","score":1,"title":["Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma"],"author":[{"given":"Mark R.","family":"Dowling","sequence":"first","affiliation":[{"name":"1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia"},{"name":"2The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia"},{"name":"3Centre of Excellence in Cellular Immunotherapy, Peter MacCallum Cancer Centre, Melbourne, Australia"}]},{"given":"Edward R. Scheffer","family":"Cliff","sequence":"additional","affiliation":[{"name":"1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia"},{"name":"2The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia"}]},{"given":"Anthony","family":"Jeffrey","sequence":"additional","affiliation":[{"name":"4Department of Haematology, Royal Prince Alfred Hospital, Camperdown, Australia"},{"name":"5Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia"}]},{"given":"Catelyn","family":"Cashion","sequence":"additional","affiliation":[{"name":"6Blood Transplant and Cell Therapies Program, Department of Haematology, Westmead Hospital, Sydney, Australia"}]},{"given":"Stephen","family":"Boyle","sequence":"additional","affiliation":[{"name":"7Cancer Care Services, Royal Brisbane and Women's Hospital, Metro North Hospital and Health Service, Brisbane, Australia"},{"name":"8Translational Cancer Immunotherapy Laboratory, QIMR Berghofer, Brisbane, Australia"},{"name":"9Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane, Australia"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[{"name":"10Malignant Haematology, Transplantation and Cellular Therapy Service, Alfred Hospital, Melbourne, Australia"},{"name":"11Australian Centre for Blood Diseases, Monash University, Melbourne, Australia"}]},{"given":"Thomas","family":"Buss","sequence":"additional","affiliation":[{"name":"12Department of Haematology, Fiona Stanley Hospital, Murdoch, Australia"}]},{"given":"Ross","family":"MacDonald","sequence":"additional","affiliation":[{"name":"7Cancer Care Services, Royal Brisbane and Women's Hospital, Metro North Hospital and Health Service, Brisbane, Australia"}]},{"given":"Anastasia","family":"Edelkina","sequence":"additional","affiliation":[{"name":"3Centre of Excellence in Cellular Immunotherapy, Peter MacCallum Cancer Centre, Melbourne, Australia"}]},{"given":"Hamish W.","family":"Scott","sequence":"additional","affiliation":[{"name":"1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia"},{"name":"2The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia"}]},{"given":"Nicole L.","family":"O’Leary","sequence":"additional","affiliation":[{"name":"1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia"}]},{"given":"Michelle W.","family":"Keir","sequence":"additional","affiliation":[{"name":"4Department of Haematology, Royal Prince Alfred Hospital, Camperdown, Australia"}]},{"given":"Safia","family":"Belbachir","sequence":"additional","affiliation":[{"name":"12Department of Haematology, Fiona Stanley Hospital, Murdoch, Australia"}]},{"given":"David A.","family":"Westerman","sequence":"additional","affiliation":[{"name":"1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia"},{"name":"13Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia"}]},{"given":"Constantine S.","family":"Tam","sequence":"additional","affiliation":[{"name":"10Malignant Haematology, Transplantation and Cellular Therapy Service, Alfred Hospital, Melbourne, Australia"},{"name":"11Australian Centre for Blood Diseases, Monash University, Melbourne, Australia"}]},{"given":"P. Joy","family":"Ho","sequence":"additional","affiliation":[{"name":"4Department of Haematology, Royal Prince Alfred Hospital, Camperdown, Australia"},{"name":"5Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia"}]},{"given":"Simon J.","family":"Harrison","sequence":"additional","affiliation":[{"name":"1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia"},{"name":"2The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia"},{"name":"3Centre of Excellence in Cellular Immunotherapy, Peter MacCallum Cancer Centre, Melbourne, Australia"}]},{"given":"Allison","family":"Barraclough","sequence":"additional","affiliation":[{"name":"12Department of Haematology, Fiona Stanley Hospital, Murdoch, Australia"}]},{"given":"Shafqat","family":"Inam","sequence":"additional","affiliation":[{"name":"10Malignant Haematology, Transplantation and Cellular Therapy Service, Alfred Hospital, Melbourne, Australia"}]},{"given":"Emily","family":"Blyth","sequence":"additional","affiliation":[{"name":"5Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia"},{"name":"6Blood Transplant and Cell Therapies Program, Department of Haematology, Westmead Hospital, Sydney, Australia"},{"name":"14Centre for Cancer Research, Westmead Institute for Medical Research, Sydney, Australia"}]},{"given":"Andrea S.","family":"Henden","sequence":"additional","affiliation":[{"name":"7Cancer Care Services, Royal Brisbane and Women's Hospital, Metro North Hospital and Health Service, Brisbane, Australia"},{"name":"8Translational Cancer Immunotherapy Laboratory, QIMR Berghofer, Brisbane, Australia"},{"name":"9Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane, Australia"}]},{"given":"Vinay","family":"Vanguru","sequence":"additional","affiliation":[{"name":"4Department of Haematology, Royal Prince Alfred Hospital, Camperdown, Australia"},{"name":"5Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia"}]},{"given":"Michael J.","family":"Dickinson","sequence":"additional","affiliation":[{"name":"1Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia"},{"name":"2The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia"},{"name":"3Centre of Excellence in Cellular Immunotherapy, Peter MacCallum Cancer Centre, Melbourne, Australia"}]}],"issued":{"date-parts":[[2026,5,7]]},"member":"234","prefix":"10.1182","source":"Crossref","volume":"147","created":{"date-time":"2026-02-17T22:03:56Z","timestamp":1771365836000,"date-parts":[[2026,2,17]]},"indexed":{"date-time":"2026-05-08T00:05:37Z","timestamp":1778198737604,"date-parts":[[2026,5,8]]},"subject":[],"abstract":"\n Abstract\n In this retrospective analysis of 584 patients who received chimeric antigen receptor T-cell therapy for large B-cell lymphoma at 6 Australian centers, no association was found between time of infusion and outcome, accounting for confounders, suggesting minimal clinical impact of chronobiology in this setting.\n ","language":"en","relation":{},"resource":{"primary":{"URL":"https://ashpublications.org/blood/article/147/19/2272/566631/Time-of-infusion-does-not-significantly-impact"}},"subtitle":[],"deposited":{"date-time":"2026-05-07T15:22:06Z","timestamp":1778167326000,"date-parts":[[2026,5,7]]},"issn-type":[{"type":"print","value":"0006-4971"},{"type":"electronic","value":"1528-0020"}],"published":{"date-parts":[[2026,5,7]]},"publisher":"American Society of Hematology","reference":[{"DOI":"10.1016/S1470-2045(21)00546-5","key":"2026050711215554100_bib1","year":"2021","issue":"12","author":"Qian","volume":"22","first-page":"1777","unstructured":null,"article-title":"Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study","journal-title":"Lancet Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ebiom.2025.105607","key":"2026050711215554100_bib2","year":"2025","issue":null,"author":"Huang","volume":"113","first-page":"105607","unstructured":null,"article-title":"Overall survival according to time-of-day of combined immuno-chemotherapy for advanced non-small cell lung cancer: a bicentric bicontinental study","journal-title":"EBioMedicine","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ejca.2023.01.007","key":"2026050711215554100_bib3","year":"2023","issue":null,"author":"Rousseau","volume":"182","first-page":"107","unstructured":null,"article-title":"Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer","journal-title":"Eur J Cancer","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.clgc.2023.06.004","key":"2026050711215554100_bib4","year":"2023","issue":"5","author":"Dizman","volume":"21","first-page":"530","unstructured":null,"article-title":"Association between time-of-day of immune checkpoint blockade administration and outcomes in metastatic renal cell carcinoma","journal-title":"Clin Genitourin Cancer","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.esmoop.2023.102220","key":"2026050711215554100_bib5","year":"2024","issue":"2","author":"Landré","volume":"9","first-page":"102220","unstructured":null,"article-title":"Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis","journal-title":"ESMO Open","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41591-025-04181-w","key":"2026050711215554100_bib6","year":"2 2026","issue":null,"author":"Huang","volume":null,"first-page":null,"unstructured":null,"article-title":"Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial","journal-title":"Nat Med","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.immuni.2014.02.002","key":"2026050711215554100_bib7","year":"2014","issue":"2","author":"Curtis","volume":"40","first-page":"178","unstructured":null,"article-title":"Circadian clock proteins and immunity","journal-title":"Immunity","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41590-024-01859-0","key":"2026050711215554100_bib8","year":"2024","issue":"7","author":"Fortin","volume":"25","first-page":"1257","unstructured":null,"article-title":"Circadian control of tumor immunosuppression affects efficacy of immune checkpoint blockade","journal-title":"Nat Immunol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cell.2024.04.015","key":"2026050711215554100_bib9","year":"2024","issue":"11","author":"Wang","volume":"187","first-page":"2690","unstructured":null,"article-title":"Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy","journal-title":"Cell","doi-asserted-by":"crossref"},{"DOI":null,"key":"2026050711215554100_bib10","year":"2023","issue":"19","author":"Neelapu","volume":"141","first-page":"2307","unstructured":null,"article-title":"5-Year follow-up supports curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1)","journal-title":"Blood","doi-asserted-by":null},{"DOI":"10.1182/blood-2017-03-769620","key":"2026050711215554100_bib11","year":"2017","issue":"16","author":"Crump","volume":"130","first-page":"1800","unstructured":null,"article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1172/jci.insight.201159","key":"2026050711215554100_bib12","year":"2025","issue":"3","author":"Lyons","volume":"11","first-page":"e201159","unstructured":null,"article-title":"Diurnal rhythm in chimeric antigen receptor T-cell effectiveness in an observational study of 715 patients","journal-title":"JCI Insight","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.2025031476","key":"2026050711215554100_bib13","year":"2026","issue":"12","author":"Luan","volume":"147","first-page":"1315","unstructured":null,"article-title":"Time of day of CAR T-Cell infusion and outcomes in large B-cell lymphoma","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41591-022-01969-y","key":"2026050711215554100_bib14","year":"2022","issue":"10","author":"Bachy","volume":"28","first-page":"2145","unstructured":null,"article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","journal-title":"Nat Med","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood-2023-186510","key":"2026050711215554100_bib15","year":"2023","issue":"suppl 1","author":"Buecklein","volume":"142","first-page":"3787","unstructured":null,"article-title":"Impact of sex on clinical outcomes after CD19 CAR T-cell therapy for large B-cell lymphoma: response and survival are significantly superior in female compared to male patients [abstract]","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1182/bloodadvances.2020002394","key":"2026050711215554100_bib16","year":"2020","issue":"19","author":"Locke","volume":"4","first-page":"4898","unstructured":null,"article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","journal-title":"Blood Adv","doi-asserted-by":"crossref"},{"DOI":null,"key":"2026050711215554100_bib17","year":"2022","issue":"9","author":"Jacobson","volume":"28","first-page":"581.e1.581.e8","unstructured":null,"article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States","journal-title":"Transplant Cell Ther","doi-asserted-by":null},{"DOI":"10.1056/NEJMoa2301665","key":"2026050711215554100_bib18","year":"2023","issue":"2","author":"Westin","volume":"389","first-page":"148","unstructured":null,"article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1182/bloodadvances.2022009019","key":"2026050711215554100_bib19","year":"2023","issue":"12","author":"Roddie","volume":"7","first-page":"2872","unstructured":null,"article-title":"Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma","journal-title":"Blood Adv","doi-asserted-by":"crossref"},{"DOI":null,"key":"2026050711215554100_bib20","year":"16 2025","issue":null,"author":"Lyons","volume":null,"first-page":"2025.05.15.25327612","unstructured":null,"article-title":"Diurnal rhythms in chimeric antigen receptor T cell performance: an observational study of 670 patients","journal-title":"medRxiv","doi-asserted-by":null}],"short-title":[],"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,5,7]]}},"update-policy":"https://doi.org/10.1182/blood.2019cm0000","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"original-title":[],"container-title":["Blood"],"published-other":{"date-parts":[[2026,5,7]]},"published-print":{"date-parts":[[2026,5,7]]},"reference-count":20,"published-online":null,"references-count":20,"short-container-title":[],"is-referenced-by-count":1},"unpaywall":{"doi":"10.1182/blood.2025032307","is_oa":false,"title":"Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma","updated":"2026-02-18T08:34:54+00:00","published_date":"2026-02-17","best_oa_location":null}},"created_at":"2026-05-14T13:22:59.302Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1182/blood.2025032307","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1182/blood.2025032307","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1182/blood.2025032307","tag_type":"condition","value":"Large B-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1182/blood.2025032307","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1182/blood.2025032307","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1182/blood.2025032307","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1182/blood.2025032307","tag_type":"modality","value":"CAR T-Cell Therapy","value_numeric":null},{"paper_doi":"10.1182/blood.2025032307","tag_type":"sample_size","value":"n=584","value_numeric":584},{"paper_doi":"10.1182/blood.2025032307","tag_type":"study_design","value":"Retrospective Cohort","value_numeric":null},{"paper_doi":"10.1182/blood.2025032307","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1182/blood.2025032307","tag_type":"warning","value":"Only the abstract language was available; specific outcomes measured and time-of-day categories were not detailed.","value_numeric":null},{"paper_doi":"10.1182/blood.2025032307","tag_type":"warning","value":"Sex distribution of the cohort is not reported in the abstract; the sex tag has been omitted.","value_numeric":null},{"paper_doi":"10.1182/blood.2025032307","tag_type":"warning","value":"The abstract does not specify which outcome measures (e.g., overall survival, complete response rate, progression-free survival) were analyzed, limiting interpretation of 'outcomes'.","value_numeric":null},{"paper_doi":"10.1182/blood.2025032307","tag_type":"warning","value":"The impact_flag 'practice_changing' is applied cautiously — this study refutes a proposed optimization strategy (chronotherapy timing) rather than introducing a new one.","value_numeric":null},{"paper_doi":"10.1182/blood.2025032307","tag_type":"warning","value":"The study is described as a retrospective analysis; exact cohort definitions and statistical methods were not specified in the abstract.","value_numeric":null}],"summaries":{"what_studied":"A retrospective analysis of 584 patients with large B-cell lymphoma across 6 Australian centers assessed whether the time of CAR T-cell infusion influenced outcomes after adjusting for confounders.","key_result":"No association was found between time of infusion and outcomes after adjustment for confounders, indicating minimal clinical impact of chronobiology in this setting.","limitations":"Retrospective design limits causal inference; data from 6 centers in a single country may limit generalizability.","practice_takeaway":"Scheduling CAR T-cell infusions by time of day is unlikely to change outcomes in large B-cell lymphoma; prioritize logistical and clinical needs over chronobiologic timing."}},{"doi":"10.1182/blood.2025031476","pmid":"41489404","title":"Time of Day of CAR T-Cell Infusion and Outcomes in Large B-Cell Lymphoma","journal_title":"Blood Journal","journal_issn":"0006-4971","published_at":"2026-01-05T00:00:00.000Z","url":"https://doi.org/10.1182/blood.2025031476","source_score":27,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2026-01-05","doi":"10.1182/blood.2025031476","days":"14","issn":"0006-4971","rank":"9","field":"Clinical Medicine","score":"27","category":"Hematology","categories":["Hematology"],"_categories":["Hematology"]},"pubmed":{"doi":"10.1182/blood.2025031476","title":"Time of Day of CAR T-Cell Infusion and Outcomes in Large B-Cell Lymphoma.","journal":"Blood","methods":"","results":"","abstract":"$30","keywords":[],"pubmed_id":"41489404","conclusions":"","publication_date":"2026-01-05T00:00:00"},"crossref":{"DOI":"10.1182/blood.2025031476","URL":"https://doi.org/10.1182/blood.2025031476","ISSN":["0006-4971","1528-0020"],"link":[{"URL":"https://ashpublications.org/blood/article-pdf/doi/10.1182/blood.2025031476/2477383/blood.2025031476.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https://ashpublications.org/blood/article-pdf/doi/10.1182/blood.2025031476/2477383/blood.2025031476.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Time of Day of CAR T-Cell Infusion and Outcomes in Large B-Cell Lymphoma"],"author":[{"given":"Danny","family":"Luan","sequence":"first","affiliation":[{"name":"Weill Cornell Medical College, New York, New York, United States"}]},{"given":"Ori Ben","family":"Valid","sequence":"additional","affiliation":[{"name":"Chaim Sheba Medical Center, Tel-Hashomer, affiliated with Faculty of MedicineTel Aviv University, Ramat Gan, Israel"}]},{"given":"Ofrat","family":"Beyar-Katz","sequence":"additional","affiliation":[{"name":"Rambam Health Care Campus, Haifa, Israel"}]},{"given":"Tobias","family":"Tix","sequence":"additional","affiliation":[{"name":"University Hospital, LMU Munich, Munich, Germany"}]},{"given":"Noa","family":"Golan-Accav","sequence":"additional","affiliation":[{"name":"Chaim Sheba Medical Center, Tel-Hashomer, affiliated with Faculty of MedicineTel Aviv University, Ramat Gan, Israel"}]},{"given":"Mohammad","family":"Alhomoud","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, United States"}]},{"given":"Abraham","family":"Avigdor","sequence":"additional","affiliation":[{"name":"Sheba Medical Center, Tel Hashomer, Israel"}]},{"given":"Veit L.","family":"Bücklein","sequence":"additional","affiliation":[{"name":"University Hospital, LMU Munich, Munich, Germany"}]},{"given":"Limor","family":"Cohen","sequence":"additional","affiliation":[{"name":"Ben-Gurion University of the Negev, Beer-Sheva, Israel"}]},{"given":"Parastoo B","family":"Dahi","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, United States"}]},{"given":"Sigrun","family":"Einarsdottir","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, United States"}]},{"given":"Julia","family":"Elimelech","sequence":"additional","affiliation":[{"name":"Rambam Health Care Campus, Haifa, Israel"}]},{"given":"Silvia","family":"Escribano Serrat","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, United States"}]},{"given":"Lorenzo","family":"Falchi","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, United States"}]},{"given":"Teng","family":"Fei","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, United States"}]},{"given":"Sergio A.","family":"Giralt","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, United States"}]},{"given":"Marina","family":"Gomez-Llobell","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, United States"}]},{"given":"Andre","family":"Goy","sequence":"additional","affiliation":[{"name":"John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States"}]},{"given":"Nurit","family":"Horesh","sequence":"additional","affiliation":[{"name":"Rambam Health Care Campus, Haifa, Israel"}]},{"given":"Sapir","family":"Israeli","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, United States"}]},{"given":"Linus","family":"Kruk","sequence":"additional","affiliation":[{"name":"University Hospital, LMU Munich, Munich, Germany"}]},{"given":"Lori A.","family":"Leslie","sequence":"additional","affiliation":[{"name":"John Theurer Cancer Center, Hackensack, New Jersey, United States"}]},{"given":"Jennifer K","family":"Lue","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, United States"}]},{"given":"Ronit","family":"Marcus","sequence":"additional","affiliation":[{"name":"Chaim Sheba Medical Center, Ramat Gan, Israel"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[{"name":"Chaim Sheba Medical Center, Tel Hashomer, Israel"}]},{"given":"M. Lia","family":"Palomba","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, United States"}]},{"given":"Jae H","family":"Park","sequence":"additional","affiliation":[{"name":"Memorial Sloan-Kettering Cancer Center, New York, New York, United States"}]},{"given":"Sandeep S","family":"Raj","sequence":"additional","affiliation":[{"name":"MSKCC, New York, New York, United States"}]},{"given":"Siddhartha Thammineni","family":"Reddy","sequence":"additional","affiliation":[{"name":"Hackensack University Medical Center, Hackensack, New Jersey, United States"}]},{"given":"Jason T.","family":"Romancik","sequence":"additional","affiliation":[{"name":"John Theurer Cancer Center, Hackensack University Medical Center, United States"}]},{"given":"Efrat","family":"Rosenbaum","sequence":"additional","affiliation":[{"name":"Tel Aviv Sourasky Medical Center, Tel Aviv, Israel"}]},{"given":"Gilles A.","family":"Salles","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, United States"}]},{"given":"Michael","family":"Scordo","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, United States"}]},{"given":"Gunjan L.","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, United States"}]},{"given":"Avichai","family":"Shimoni","sequence":"additional","affiliation":[{"name":"Chaim Sheba Medical Center, Tel Hashomer, Israel"}]},{"given":"Michael","family":"von Bergwelt-Baildon","sequence":"additional","affiliation":[{"name":"University Hospital LMU, Munich, Germany"}]},{"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, United States"}]},{"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[{"name":"University Hospital, LMU Munich, Munich, Germany"}]},{"given":"Uri","family":"Greenbaum","sequence":"additional","affiliation":[{"name":"Soroka University Medical Center, Beer Sheva, Israel"}]},{"given":"Andrew","family":"Ip","sequence":"additional","affiliation":[{"name":"John Theurer Cancer Center, Hackensack University Medical Center, Hackensack Meridian Health, Hackensack, New Jersey, United States"}]},{"given":"Ron","family":"Ram","sequence":"additional","affiliation":[{"name":"Tel Aviv Sourasky Medical Center, Tel Aviv, Israel"}]},{"given":"Kai","family":"Rejeski","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, United States"}]},{"given":"Roni","family":"Shouval","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, United States"}]}],"issued":{"date-parts":[[2025,12,23]]},"member":"234","prefix":"10.1182","source":"Crossref","volume":null,"created":{"date-time":"2026-01-05T14:10:31Z","timestamp":1767622231000,"date-parts":[[2026,1,5]]},"indexed":{"date-time":"2026-01-05T18:02:42Z","timestamp":1767636162232,"date-parts":[[2026,1,5]]},"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://ashpublications.org/blood/article/doi/10.1182/blood.2025031476/557451/Time-of-Day-of-CAR-T-Cell-Infusion-and-Outcomes-in"}},"subtitle":[],"deposited":{"date-time":"2026-01-05T14:10:32Z","timestamp":1767622232000,"date-parts":[[2026,1,5]]},"issn-type":[{"type":"print","value":"0006-4971"},{"type":"electronic","value":"1528-0020"}],"published":{"date-parts":[[2025,12,23]]},"publisher":"American Society of Hematology","reference":null,"short-title":[],"update-policy":"https://doi.org/10.1182/blood.2019cm0000","article-number":"blood.2025031476","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"original-title":[],"container-title":["Blood Journal"],"reference-count":0,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,12,23]]},"references-count":0,"short-container-title":[],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1182/blood.2025031476","is_oa":false,"title":"Time of Day of CAR T-Cell Infusion and Outcomes in Large B-Cell Lymphoma","updated":"2026-01-06T03:47:31+00:00","published_date":"2025-12-23","best_oa_location":null}},"created_at":"2026-01-11T11:19:33.869Z","updated_at":"2026-01-19T09:31:36.873Z","tags":[{"paper_doi":"10.1182/blood.2025031476","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1182/blood.2025031476","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1182/blood.2025031476","tag_type":"condition","value":"Large B-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1182/blood.2025031476","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1182/blood.2025031476","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1182/blood.2025031476","tag_type":"modality","value":"CAR T-Cell Therapy","value_numeric":null},{"paper_doi":"10.1182/blood.2025031476","tag_type":"sample_size","value":"n=1,052","value_numeric":1052},{"paper_doi":"10.1182/blood.2025031476","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1182/blood.2025031476","tag_type":"warning","value":"Infusion timing was observational and not randomized, which can leave residual confounding.","value_numeric":null},{"paper_doi":"10.1182/blood.2025031476","tag_type":"warning","value":"Only 1‑year PFS is reported; detailed OS metrics are not provided in the abstract.","value_numeric":null},{"paper_doi":"10.1182/blood.2025031476","tag_type":"warning","value":"Specific CD19 CAR T products are not listed in the abstract; product heterogeneity may influence results.","value_numeric":null}],"summaries":{"what_studied":"We reviewed 1,052 adults with relapsed or refractory large B‑cell lymphoma treated with CD19‑directed CAR T across seven centers (2017–2025) to test whether time of day of infusion affects outcomes. Early (<12:00 PM) versus late (≥12:00 PM) infusion and per‑hour timing were examined with adjustment for center, product, and clinical variables.","key_result":"Each hour later in infusion time was linked to higher risk of progression, relapse, or death (HR 1.11; 95% CI 1.03–1.20; P=0.004). One‑year PFS was 51.4% with early infusion versus 35.2% with late infusion; overall survival was similar, and late infusion correlated with higher peak inflammatory markers and reduced day‑7 CAR T expansion without differences in immune toxicities.","limitations":"Retrospective, non‑randomized timing across multiple centers limits causal inference. Multiple CD19 CAR T products and sites may introduce heterogeneity despite adjustment, and overall survival did not differ between groups.","practice_takeaway":"Morning (<12:00 PM) CAR T infusions were associated with better 1‑year PFS without more immune toxicities. When feasible, consider scheduling earlier‑day infusions while awaiting prospective confirmation."}},{"doi":"10.1182/bloodadvances.2025016968","pmid":"41124653","title":"Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortium","journal_title":"Blood Advances","journal_issn":"2473-9529","published_at":"2025-10-22T00:00:00.000Z","url":"https://doi.org/10.1182/bloodadvances.2025016968","source_score":14,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-01-11","doi":"10.1182/bloodadvances.2025016968","days":"7","issn":"2473-9529","rank":"10","field":"Clinical Medicine","score":"14","category":"Hematology","categories":["Hematology"],"_categories":["Hematology"]},"pubmed":{"doi":"10.1182/bloodadvances.2025016968","title":"Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortium.","journal":"Blood advances","methods":"","results":"","abstract":"","keywords":[],"pubmed_id":"41124653","conclusions":"","publication_date":"2025-10-22T00:00:00"},"crossref":{"DOI":"10.1182/bloodadvances.2025016968","URL":"https://doi.org/10.1182/bloodadvances.2025016968","ISSN":["2473-9529","2473-9537"],"link":[{"URL":"https://ashpublications.org/bloodadvances/article-pdf/10/1/228/2497025/blooda_adv-2025-016968-main.pdf","content-type":"application/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https://ashpublications.org/bloodadvances/article-pdf/10/1/228/2497025/blooda_adv-2025-016968-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"228-232","type":"journal-article","issue":"1","score":1,"title":["Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortium"],"author":[{"given":"Megan","family":"Melody","sequence":"first","affiliation":[{"name":"1Department of Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL"},{"name":"2Department of Hematology, Oncology, and Cellular Therapy, Tampa General Hospital Cancer Institute, Tampa, FL"}]},{"given":"Natalie","family":"Grover","sequence":"additional","affiliation":[{"name":"3Division of Hematology, The University of North Carolina at Chapel Hill, Chapel Hill, NC"}]},{"given":"Stephanie","family":"Franco","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL"}]},{"given":"Jason","family":"Romancik","sequence":"additional","affiliation":[{"name":"4Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA"}]},{"given":"Matthew","family":"Cortese","sequence":"additional","affiliation":[{"name":"5Department of Hematology and Medical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY"}]},{"given":"Tamara K.","family":"Moyo","sequence":"additional","affiliation":[{"name":"6Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC"}]},{"given":"Rahul S.","family":"Bhansali","sequence":"additional","affiliation":[{"name":"7Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}]},{"given":"Thomas","family":"Ollila","sequence":"additional","affiliation":[{"name":"8Division of Hematology and Oncology, Lifespan Cancer Institute, Brown University, Providence, RI"}]},{"given":"Vaishalee","family":"Kenkre","sequence":"additional","affiliation":[{"name":"9Division of Hematology/Oncology, Carbone Cancer Center, University of Wisconsin–Madison, Madison, WI"}]},{"given":"Lindsey","family":"Fitzgerald","sequence":"additional","affiliation":[{"name":"10Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT"}]},{"given":"Brian","family":"Hess","sequence":"additional","affiliation":[{"name":"11Division of Hematology and Medical Oncology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC"}]},{"given":"Matt","family":"Matasar","sequence":"additional","affiliation":[{"name":"12Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ"}]},{"given":"Geoffrey","family":"Shouse","sequence":"additional","affiliation":[{"name":"13Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA"}]},{"given":"Kaitlin","family":"Annunzio","sequence":"additional","affiliation":[{"name":"14Division of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH"}]},{"given":"Megan M.","family":"Herr","sequence":"additional","affiliation":[{"name":"5Department of Hematology and Medical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY"}]},{"given":"James A.","family":"Davis","sequence":"additional","affiliation":[{"name":"11Division of Hematology and Medical Oncology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC"}]},{"given":"Christy","family":"Jesme","sequence":"additional","affiliation":[{"name":"10Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT"}]},{"given":"Ari","family":"Pelcovits","sequence":"additional","affiliation":[{"name":"8Division of Hematology and Oncology, Lifespan Cancer Institute, Brown University, Providence, RI"}]},{"given":"Jonathan","family":"Moreira","sequence":"additional","affiliation":[{"name":"15Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"}]},{"given":"Shuo","family":"Ma","sequence":"additional","affiliation":[{"name":"15Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"}]},{"given":"Jane N.","family":"Winter","sequence":"additional","affiliation":[{"name":"15Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"}]},{"given":"Adam","family":"Lin","sequence":"additional","affiliation":[{"name":"15Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"}]},{"given":"Alexey","family":"Danilov","sequence":"additional","affiliation":[{"name":"13Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA"}]},{"given":"Ishan","family":"Roy","sequence":"additional","affiliation":[{"name":"16Shirley Ryan Ability Lab, Chicago, IL"},{"name":"17Department of Physical Medicine and Rehabilitation, Northwestern University, Chicago, IL"}]},{"given":"Stefan K.","family":"Barta","sequence":"additional","affiliation":[{"name":"7Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}]},{"given":"Leo I","family":"Gordon","sequence":"additional","affiliation":[{"name":"15Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"}]},{"given":"Deborah","family":"Stephens","sequence":"additional","affiliation":[{"name":"3Division of Hematology, The University of North Carolina at Chapel Hill, Chapel Hill, NC"}]},{"given":"Jonathon B.","family":"Cohen","sequence":"additional","affiliation":[{"name":"4Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA"}]},{"given":"Narendranath","family":"Epperla","sequence":"additional","affiliation":[{"name":"14Division of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH"}]},{"given":"Reem","family":"Karmali","sequence":"additional","affiliation":[{"name":"15Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL"}]}],"issued":{"date-parts":[[2026,1,5]]},"member":"234","prefix":"10.1182","source":"Crossref","volume":"10","created":{"date-time":"2025-10-22T20:15:59Z","timestamp":1761164159000,"date-parts":[[2025,10,22]]},"indexed":{"date-time":"2026-01-13T21:08:59Z","timestamp":1768338539792,"date-parts":[[2026,1,13]]},"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://ashpublications.org/bloodadvances/article/10/1/228/547867/Outcomes-of-bispecific-antibodies-after-CAR-T-cell"}},"subtitle":[],"deposited":{"date-time":"2026-01-13T14:01:51Z","timestamp":1768312911000,"date-parts":[[2026,1,13]]},"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"published":{"date-parts":[[2026,1,5]]},"publisher":"American Society of Hematology","reference":[{"DOI":"10.1182/blood.2023020854","key":"2026011309014295900_bib1","year":"2024","issue":"5","author":"Abramson","volume":"143","first-page":"404","unstructured":null,"article-title":"Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":null,"key":"2026011309014295900_bib2","year":"2023","issue":"19","author":"Neelapu","volume":"141","first-page":"2307","unstructured":null,"article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","journal-title":"Blood","doi-asserted-by":null},{"DOI":"10.1016/S1470-2045(21)00375-2","key":"2026011309014295900_bib3","year":"2021","issue":"10","author":"Schuster","volume":"22","first-page":"1403","unstructured":null,"article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","journal-title":"Lancet Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa2301665","key":"2026011309014295900_bib4","year":"2023","issue":"2","author":"Westin","volume":"389","first-page":"148","unstructured":null,"article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jtct.2023.09.008","key":"2026011309014295900_bib5","year":"2023","issue":"12","author":"Derigs","volume":"29","first-page":"750","unstructured":null,"article-title":"Long-term survivors after failure of chimeric antigen receptor T cell therapy for large B cell lymphoma: a role for allogeneic hematopoietic cell transplantation? A German Lymphoma Alliance and German Registry for Stem Cell Transplantation Analysis","journal-title":"Transplant Cell Ther","doi-asserted-by":"crossref"},{"DOI":"10.1182/bloodadvances.2022008240","key":"2026011309014295900_bib6","year":"2023","issue":"12","author":"Zurko","volume":"7","first-page":"2657","unstructured":null,"article-title":"Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL","journal-title":"Blood Adv","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMoa2206913","key":"2026011309014295900_bib7","year":"2022","issue":"24","author":"Dickinson","volume":"387","first-page":"2220","unstructured":null,"article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","journal-title":"N Engl J Med","doi-asserted-by":"crossref"},{"DOI":"10.1200/JCO.22.01725","key":"2026011309014295900_bib8","year":"2023","issue":"12","author":"Thieblemont","volume":"41","first-page":"2238","unstructured":null,"article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial","journal-title":"J Clin Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1186/s12967-022-03442-3","key":"2026011309014295900_bib9","year":"2022","issue":"1","author":"Kouro","volume":"20","first-page":"239","unstructured":null,"article-title":"Exhaustion of CAR T cells: potential causes and solutions","journal-title":"J Transl Med","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.2022015956","key":"2026011309014295900_bib10","year":"2022","issue":"10","author":"Philipp","volume":"140","first-page":"1104","unstructured":null,"article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1016/S2352-3026(24)00186-8","key":"2026011309014295900_bib11","year":"2024","issue":"9","author":"van de Donk","volume":"11","first-page":"e693","unstructured":null,"article-title":"Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies","journal-title":"Lancet Haematol","doi-asserted-by":"crossref"},{"DOI":"10.3389/fcell.2022.1034257","key":"2026011309014295900_bib12","year":"2022","issue":null,"author":"Zhu","volume":"10","first-page":"1034257","unstructured":null,"article-title":"Mechanisms of CAR T cell exhaustion and current counteraction strategies","journal-title":"Front Cell Dev Biol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jtct.2023.12.493","key":"2026011309014295900_bib13","year":"2024","issue":"2","author":"Epperla","volume":"30","first-page":"S353","unstructured":null,"article-title":"Real-world clinical effectiveness of loncastuximab tesirine monotherapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma following chimeric antigen T cell therapy in the US","journal-title":"Transplant Cell Ther","doi-asserted-by":"crossref"},{"DOI":"10.1200/JCO-24-02242","key":"2026011309014295900_bib14","year":"2025","issue":"9","author":"Bartlett","volume":"43","first-page":"1061","unstructured":null,"article-title":"Brentuximab vedotin combination for relapsed diffuse large B-cell lymphoma","journal-title":"J Clin Oncol","doi-asserted-by":"crossref"}],"short-title":[],"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,13]]}},"update-policy":"https://doi.org/10.1182/blood.2019cm0000","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"original-title":[],"container-title":["Blood Advances"],"published-other":{"date-parts":[[2026,1,13]]},"published-print":{"date-parts":[[2026,1,13]]},"reference-count":14,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,1,5]]},"references-count":14,"short-container-title":[],"is-referenced-by-count":1},"unpaywall":{"doi":"10.1182/bloodadvances.2025016968","is_oa":true,"title":"Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortium","updated":"2026-01-10T04:46:20+00:00","published_date":"2025-10-22","best_oa_location":{"url":"https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2025016968/2417823/bloodadvances.2025016968.pdf","pmh_id":null,"url_for_pdf":"https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2025016968/2417823/bloodadvances.2025016968.pdf","url_for_landing_page":"https://doi.org/10.1182/bloodadvances.2025016968"}}},"created_at":"2026-01-14T18:30:49.575Z","updated_at":"2026-01-17T09:03:27.421Z","tags":[{"paper_doi":"10.1182/bloodadvances.2025016968","tag_type":"category","value":"Hematology","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025016968","tag_type":"condition","value":"Large B-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025016968","tag_type":"modality","value":"Bispecific Antibody","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025016968","tag_type":"warning","value":"Only the article title and citation were available; no methods, sample size, or outcomes were provided.","value_numeric":null},{"paper_doi":"10.1182/bloodadvances.2025016968","tag_type":"warning","value":"Study design and effect sizes cannot be determined from the provided text.","value_numeric":null}],"summaries":{"what_studied":"Evaluated outcomes of bispecific antibodies used after CAR T-cell therapy failure in large B-cell lymphoma, drawing on data from the ABC consortium."}},{"doi":"10.1200/jco-25-01534","pmid":"40802906","title":"Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma","journal_title":"Journal of Clinical Oncology","journal_issn":"0732-183X","published_at":"2025-08-13T00:00:00.000Z","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/12363663","source_score":73,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-11-29","doi":"10.1200/jco-25-01534","days":"7","issn":"0732-183X","rank":"4","field":"Clinical Medicine","score":"73","category":"Oncology","categories":["Oncology"],"_categories":["Oncology"]},"pubmed":{"doi":"10.1200/JCO-25-01534","title":"Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma.","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","methods":"","results":"We studied ctDNA-MRD in 137 patients by monitoring 409 plasma specimens over time. Detectable ctDNA rates decreased during therapy with 55% and 78% of patients achieving undetectable ctDNA after two cycles and at the end of therapy, respectively. After a median follow-up of 37 months, the 2-year PFS for patients with detectable versus undetectable ctDNA after two cycles was 67% versus 96% (","abstract":"$32","keywords":[],"pubmed_id":"40802906","conclusions":"Ultrasensitive ctDNA detection after frontline LBCL therapy is more prognostic than conventional radiographic response criteria. A refined definition of remission with ctDNA-MRD may improve clinical and psychological outcomes for patients with LBCL.","publication_date":"2025-08-13T00:00:00"},"crossref":{"DOI":"10.1200/jco-25-01534","URL":"https://doi.org/10.1200/jco-25-01534","ISSN":["0732-183X","1527-7755"],"link":[{"URL":"https://ascopubs.org/doi/pdfdirect/10.1200/JCO-25-01534","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"3652-3661","type":"journal-article","issue":"34","score":1,"title":["Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma"],"author":[{"given":"Mark","family":"Roschewski","sequence":"first","affiliation":[{"name":"Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD"}]},{"given":"David M.","family":"Kurtz","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Stanford University, Stanford, CA"},{"name":"Stanford Cancer Institute, Stanford University, Stanford, CA"},{"name":"Foresight Diagnostics, Boulder, CO"}]},{"given":"Jason R.","family":"Westin","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}]},{"given":"Ryan C.","family":"Lynch","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Department of Medicine, University of Washington School of Medicine Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA"}]},{"given":"Ajay K.","family":"Gopal","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Department of Medicine, University of Washington School of Medicine Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA"}]},{"given":"Stefan K.","family":"Alig","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Stanford University, Stanford, CA"},{"name":"Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany"}]},{"given":"Brian J.","family":"Sworder","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Department of Medicine, University of California, Irvine School of Medicine, Irvine, CA"}]},{"given":"Hua-Jay J.","family":"Cherng","sequence":"additional","affiliation":[{"name":"Division of Hematology & Oncology, Columbia University Irving Medical Center, New York, NY"}]},{"given":"Christian","family":"Kuffer","sequence":"additional","affiliation":[{"name":"MorphoSys, a Novartis Company, Planegg, Germany"}]},{"given":"Derek","family":"Blair","sequence":"additional","affiliation":[{"name":"MorphoSys, a Novartis Company, Planegg, Germany"}]},{"given":"Krystal","family":"Brown","sequence":"additional","affiliation":[{"name":"Foresight Diagnostics, Boulder, CO"}]},{"given":"Jordan S.","family":"Goldstein","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Stanford University, Stanford, CA"}]},{"given":"Andre","family":"Schultz","sequence":"additional","affiliation":[{"name":"Foresight Diagnostics, Boulder, CO"}]},{"given":"Sandra","family":"Close","sequence":"additional","affiliation":[{"name":"Foresight Diagnostics, Boulder, CO"}]},{"given":"Jacob J.","family":"Chabon","sequence":"additional","affiliation":[{"name":"Foresight Diagnostics, Boulder, CO"}]},{"given":"Maximilian","family":"Diehn","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute, Stanford University, Stanford, CA"},{"name":"Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA"},{"name":"Department of Radiation Oncology, Stanford University, Stanford, CA"}]},{"given":"Wyndham H.","family":"Wilson","sequence":"additional","affiliation":[{"name":"Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD"}]},{"given":"Ash A.","family":"Alizadeh","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Stanford University, Stanford, CA"},{"name":"Stanford Cancer Institute, Stanford University, Stanford, CA"},{"name":"Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA"}]}],"issued":{"date-parts":[[2025,12]]},"member":"233","prefix":"10.1200","source":"Crossref","volume":"43","created":{"date-time":"2025-08-13T19:59:09Z","timestamp":1755115149000,"date-parts":[[2025,8,13]]},"indexed":{"date-time":"2025-11-24T23:01:54Z","timestamp":1764025314412,"date-parts":[[2025,11,24]]},"subject":[],"abstract":"$33","language":"en","relation":{},"resource":{"primary":{"URL":"https://ascopubs.org/doi/10.1200/JCO-25-01534"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-06-27"},{"name":"revised","group":{"name":"publication_history","label":"Publication History"},"label":"Revised","order":1,"value":"2025-07-15"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-08-08"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2025-08-13"}],"deposited":{"date-time":"2025-11-24T22:59:40Z","timestamp":1764025180000,"date-parts":[[2025,11,24]]},"issn-type":[{"type":"print","value":"0732-183X"},{"type":"electronic","value":"1527-7755"}],"published":{"date-parts":[[2025,12]]},"publisher":"American Society of Clinical Oncology (ASCO)","reference":[{"DOI":"10.1200/JCO.2013.54.8800","key":"e_1_3_10_2_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bjh.13420","key":"e_1_3_10_3_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1080/10428194.2022.2095624","key":"e_1_3_10_4_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2009.26.5942","key":"e_1_3_10_5_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3324/haematol.2018.192492","key":"e_1_3_10_6_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2012.45.4801","key":"e_1_3_10_7_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1177/1359105315607828","key":"e_1_3_10_8_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2005.01.891","key":"e_1_3_10_9_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2006.09.2403","key":"e_1_3_10_10_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2013.53.5229","key":"e_1_3_10_11_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1182/bloodadvances.2020002690","key":"e_1_3_10_12_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1182/blood.2019003277","key":"e_1_3_10_13_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1182/blood-2016-05-718528","key":"e_1_3_10_14_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1056/NEJMra1706174","key":"e_1_3_10_15_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(15)70106-3","key":"e_1_3_10_16_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2018.78.5246","key":"e_1_3_10_17_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1182/blood-2023-187759","key":"e_1_3_10_18_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41587-021-00981-w","key":"e_1_3_10_19_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.18632/oncotarget.28719","key":"e_1_3_10_20_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1182/blood.2023020637","key":"e_1_3_10_21_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1182/bloodadvances.2022008174","key":"e_1_3_10_22_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1182/bloodadvances.2022009145","key":"e_1_3_10_23_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.23.00570","key":"e_1_3_10_24_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1182/blood-2016-04-703751","key":"e_1_3_10_25_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1182/blood-2024-207430","key":"e_1_3_10_26_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_3_10_27_2","year":null,"issue":null,"author":"National Comprehensive Cancer Network","volume":null,"first-page":null,"unstructured":"National Comprehensive Cancer Network: B-Cell Lymphomas. Version 2.2025. https://www.nccn.org","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1200/JCO.2014.55.7561","key":"e_1_3_10_28_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2014.58.5729","key":"e_1_3_10_29_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1073/pnas.2235592100","key":"e_1_3_10_30_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41591-023-02620-0","key":"e_1_3_10_31_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.19.00014","key":"e_1_3_10_32_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1158/1078-0432.CCR-18-2337","key":"e_1_3_10_33_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1182/blood.2024024371","key":"e_1_3_10_34_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1158/2643-3230.BCD-24-0292","key":"e_1_3_10_35_2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"journal-issue":{"issue":"34","published-print":{"date-parts":[[2025,12]]}},"update-policy":"https://doi.org/10.1200/crossmark","alternative-id":["10.1200/JCO-25-01534"],"content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of Clinical Oncology"],"published-print":{"date-parts":[[2025,12]]},"reference-count":34,"published-online":null,"references-count":34,"clinical-trial-number":[{"registry":"10.18810/clinical-trials-gov","clinical-trial-number":"nct00398177"},{"registry":"10.18810/clinical-trials-gov","clinical-trial-number":"nct02529852"},{"registry":"10.18810/clinical-trials-gov","clinical-trial-number":"nct04231877"},{"registry":"10.18810/clinical-trials-gov","clinical-trial-number":"nct04002947"},{"registry":"10.18810/clinical-trials-gov","clinical-trial-number":"nct04134936"}],"short-container-title":["J Clin Oncol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1200/jco-25-01534","is_oa":true,"title":"Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma","updated":"2025-10-23T16:56:47+00:00","published_date":"2025-08-13","best_oa_location":{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/12363663","pmh_id":"oai:pubmedcentral.nih.gov:12363663","url_for_pdf":null,"url_for_landing_page":"https://www.ncbi.nlm.nih.gov/pmc/articles/12363663"}}},"created_at":"2025-12-08T12:24:58.509Z","updated_at":"2025-12-08T12:24:58.509Z","tags":[{"paper_doi":"10.1200/jco-25-01534","tag_type":"category","value":"Oncology","value_numeric":null},{"paper_doi":"10.1200/jco-25-01534","tag_type":"condition","value":"Large B-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1200/jco-25-01534","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1200/jco-25-01534","tag_type":"sample_size","value":"n=137","value_numeric":137},{"paper_doi":"10.1200/jco-25-01534","tag_type":"study_design","value":"Prospective Cohort","value_numeric":null},{"paper_doi":"10.1200/jco-25-01534","tag_type":"warning","value":"Abstract text appears truncated; comparative statistics (e.g., CIs, p values) for PFS and versus imaging are not fully reported here.","value_numeric":null},{"paper_doi":"10.1200/jco-25-01534","tag_type":"warning","value":"Design classification is approximate: integrated data from five prospective studies were pooled.","value_numeric":null}],"summaries":{"what_studied":"Integrated patient-level data from five prospective frontline anthracycline-based studies in large B-cell lymphoma to test whether ultrasensitive ctDNA minimal residual disease (MRD) at landmark time points predicts progression-free survival versus conventional response criteria.","key_result":"Among 137 patients (409 plasma samples), undetectable ctDNA was achieved by 55% after two cycles and 78% at end of therapy; with 37 months median follow-up, 2-year PFS was 67% with detectable vs 96% with undetectable ctDNA after two cycles.","limitations":"Modest sample size (n=137) from pooled prospective studies; comparative performance versus radiographic response is asserted but not quantified here; PFS statistics in the provided text appear truncated (e.g., missing CIs/p values).","practice_takeaway":"Checking ctDNA-MRD early during therapy and at end of treatment stratified 2-year PFS risk (67% vs 96% after two cycles), suggesting ctDNA-MRD can refine remission assessment beyond imaging in LBCL where available."}}],"initialOffset":12,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"Large B-Cell Lymphoma"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"Large B-Cell Lymphoma"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"Large B-Cell Lymphoma"}}}]]

Papers